Navigation Links
Scripps Research announces research & license agreement with Janssen Pharmaceuticals
Date:5/7/2013

LA JOLLA, CA May 7, 2013 The Scripps Research Institute (TSRI) today announced a five-year agreement with Janssen Pharmaceuticals, Inc. (Janssen) to collaborate on focused research projects in the infectious disease area, with the initial project targeting the influenza virus. Under the agreement Janssen will receive certain license rights to the results of the research. Janssen Pharmaceuticals will collaborate in the research on influenza through its Crucell Vaccine Institute.

"We're delighted to partner with Janssen in this work that could have a significant impact on human health," said Michael A. Marletta, president and CEO of TSRI. "The new agreement leverages the institute's significant strengths in structural biology to move forward new therapies and vaccines."

Scott Forrest, TSRI's vice president for business development, added, "This deal is the latest example of our corporate partnership strategy, in which we seek focused collaborations to match companies' specific areas of interest with areas of expertise among multiple TSRI labs."

The new agreement builds on research on the influenza virus conducted jointly by TSRI and Janssen's Crucell Vaccine Institute. Previous collaborations have resulted in several high-impact publications, most recently in August 2012 in the journal Science.

Seasonal flu typically causes more than 200,000 hospitalizations and 36,000 deaths every year in the United States, according to estimates by the U.S. Centers for Disease Control. Pandemics pose a greater dangerthe Spanish Flu of 1918-1919 may have killed 50 million people worldwide.

The new strategic collaboration with Janssen follows TSRI's announcement of a five-year agreement with Bristol-Myers Squibb last June; that agreement covered the development of chemistry methodologies and related work.

Forrest notes that promising future areas for corporate partnerships at TSRI include Oncology, Neurodegeneration and Immunology.


'/>"/>

Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps Research discoveries lead to newly approved drug for infant respiratory distress syndrome
2. Scripps Research Institute scientists find promising vaccine targets on hepatitis C virus
3. Scripps Research Institute Professor Gerald F. Joyce elected to American Academy of Arts & Sciences
4. Scripps Research Institute scientists develop antidote for cocaine overdose
5. Scientist wins $3 million renewal of one of longest-running NIH grants to Scripps Research
6. Scripps research scientists find anticonvulsant drug helps marijuana smokers kick the habit
7. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
8. Scripps Florida scientists identify neurotranmitters that lead to forgetting
9. Plastic trash altering ocean habitats, Scripps study shows
10. Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments
11. Esther B. OKeeffe Foundation gives $2 million to the Scripps Research Institute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2019)... , ... October 04, 2019 , ... ... will be held November 10 at the Grand Elysée Hamburg Rothenbaumchaussee in Hamburg. ... Europe again this November,” said Miao Guo, Vice President of Operations and spokesperson ...
(Date:10/3/2019)... ... October 01, 2019 , ... The ... of chemicals, reagents, and medias and to be a more environmentally sustainable evolution ... culmination of years of experience and feedback from the original version we launched ...
(Date:10/3/2019)... ... 02, 2019 , ... Connecticut Innovations (CI), Connecticut’s strategic venture ... innovative, growing companies, today announced that it has closed on a $750,000 investment ... the 2018 VentureClash competition. , The outlay is part of ...
Breaking Biology News(10 mins):
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid Novor, Inc., ... announce that it has moved into a new, 5000 sqft, purpose-built, state-of-the-art facility. ... facility demonstrates the company's continuous commitment to quality research and service offerings. ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer ... focused on the development of therapies to treat central nervous system (CNS) ...
(Date:9/17/2019)... ... 2019 , ... Catalent, a global leader in clinical supply ... Pacific (APAC) will present at the upcoming 3rd Annual Accelerating Clinical Trials in ... Thursday, Sept. 26, at 10:10 a.m., Ms. Delaney will present “Singapore: APAC’s Clinical ...
(Date:9/17/2019)... (PRWEB) , ... September 16, 2019 , ... ... Nationwide via CNBC on Saturday, September 21st @11:00am ET. Check local listings for ... Pte. Ltd. (Credo Biomedical), a molecular diagnostic company from Singapore dedicated to ...
Breaking Biology Technology: